Cytokinetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytokinetics, Inc. on August 19, 2025. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board appointments.
Material Changes
On August 19, 2025, the Board of Directors appointed James M. Daly to fill a vacant Board seat. Mr. Daly serves as a Class III member with a term expiring at the 2028 annual meeting of stockholders. He was also appointed to the Compliance Committee. The Board determined Mr. Daly is independent under applicable SEC requirements and Nasdaq listing standards.
Compensation and Governance Details
- Annual Retainers: $50,000 for Board service and $7,500 for Compliance Committee service, both pro-rated for partial periods.
- Recurring Equity Grant: An annual grant of restricted stock units and stock options with an aggregate grant date fair value of $440,000. Vesting occurs over one year or until the subsequent annual meeting, whichever is earlier.
- Initial Grant: An option to purchase 27,450 shares of common stock with a grant date fair value of $700,000. This grant vests monthly over a three-year period.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Daly.
Investor Verification Checklist
- Verify the independence status of James M. Daly against the Company's Corporate Governance Guidelines.
- Confirm the total equity compensation value ($1,140,000 aggregate fair value) relative to the Company's current stock price and dilution impact.
- Review the vesting schedules for the Initial Grant and recurring grants to understand future liability.
- Check for any undisclosed relationships between Mr. Daly and other Company personnel as stated in the filing.